Update

Nov 21, 2011

CVS, 28th Annual Clinical Virology Symposium 20 - 25 April 2012, Daytona Beach, FL, USA

 

May 7, 2010
QuantiBact, Inc. has filed a new patent on the TINA-based Cliffhanger® PCR technology
 


"Improving Nature"


QuantiBact A/S is developing a technology that will significantly improve molecular diagnostics in the near future.

QuantiBact A/S is a biotech company founded on research regarding nucleic acid analogues performed at The University of Southern Denmark and Hvidovre Hospital.

We are developing diagnostic tools for the detection of infectious diseases by: increasing specificity, minimizing turn-around time and increasing fidelity of quantification. Our technology will significantly improve hybridization and PCR based assays.

 

 

 

  Next page: TINA Improving Diagnostics